Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer
NCT00096200
Completed
Sorafenib may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by stopping blood flow to the tumor. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving sorafenib together with chemotherapy may kill more tumor cells. This randomized phase II trial is studying how well giving sorafenib together with paclitaxel and carboplatin works in treating patients with... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
01/13/2022
Locations: Moffitt Cancer Center at Tampa General Hospital, Tampa, Florida +4 locations
Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Register for Updates
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
NCT00867178
Completed
This pilot clinical trial studies the side effects and the best way to give vorinostat with isotretinoin and combination chemotherapy and to see how well they work in treating younger patients with embryonal tumors of the central nervous system. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as isotretinoin, vincristine sulfate, cisplatin, cyclophosphamide, and etoposide phosphate, work in different ways to s... Read More
Gender:
ALL
Ages:
Between 2 months and 47 months
Trial Updated:
01/12/2022
Locations: Children's Hospital Los Angeles, Los Angeles, California +14 locations
Conditions: Medulloblastoma, Pineoblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified
Register for Updates
Combination Chemotherapy, Surgery, and Radiation Therapy in Treating Patients With Non-Small Cell Lung Cancer
NCT00043108
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving combination chemotherapy with radiation therapy before and after surgery may shrink the tumor so it can be removed during surgery and may kill any remaining tumor cells following surgery. PURPOSE: Phase II trial to study the effectiveness of combining paclitaxel and carboplatin with radiation therapy and s... Read More
Gender:
ALL
Ages:
Between 18 years and 120 years
Trial Updated:
01/05/2022
Locations: Fox Chase Cancer Center - Philadelphia, Philadelphia, Pennsylvania
Conditions: Lung Cancer
Register for Updates
Paclitaxel and Carboplatin or Bleomycin Sulfate, Etoposide Phosphate, and Cisplatin in Treating Patients With Advanced or Recurrent Sex Cord-Ovarian Stromal Tumors
NCT01042522
Unknown
This randomized phase II trial studies paclitaxel and carboplatin to see how well they work compared with bleomycin sulfate, etoposide phosphate, and cisplatin in treating patients with sex cord-ovarian stromal tumors that have spread to other places in the body and usually cannot be cured or controlled with treatment (advanced) or has returned (recurrent). Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from divi... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/30/2021
Locations: Alaska Breast Care and Surgery LLC, Anchorage, Alaska +218 locations
Conditions: Ovarian Granulosa Cell Tumor, Ovarian Gynandroblastoma, Ovarian Sertoli-Leydig Cell Tumor, Ovarian Sex Cord Tumor With Annular Tubules, Ovarian Sex Cord-Stromal Tumor, Ovarian Steroid Cell Tumor, Ovarian Sex Cord-Stromal Tumor, Not Otherwise Specified
Register for Updates
IGFBP-2 Vaccine and Combination Chemotherapy in Treating Patients With Stage III-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Undergoing Surgery
NCT03029611
Terminated
This phase II trial studies how well pUMVC3-IGFBP2 plasmid deoxyribonucleic acid (DNA) vaccine (IGFBP-2 vaccine) and combination chemotherapy work in treating patients with stage III-IV ovarian, fallopian tube, or primary peritoneal cancer undergoing surgery. IGFBP-2 is a protein found in the blood and tumor cells of most who have been diagnosed with ovarian cancer. Too much IGFBP-2 has been associated with more invasive disease. Vaccines made from DNA may help the body build an effective immune... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/17/2021
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Stage III Fallopian Tube Cancer, Stage III Ovarian Cancer, Stage III Primary Peritoneal Cancer, Stage IIIA Fallopian Tube Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Primary Peritoneal Cancer, Stage IIIB Fallopian Tube Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Primary Peritoneal Cancer, Stage IIIC Fallopian Tube Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Primary Peritoneal Cancer, Stage IV Fallopian Tube Cancer, Stage IV Ovarian Cancer, Stage IV Primary Peritoneal Cancer
Register for Updates
Concurrent Carboplatin and Reduced Dose Craniospinal Radiation for Medulloblastoma and Primitive Neuroectodermal Tumor (PNET)
NCT01542736
Completed
The purpose of this study is to study the efficacy of the combination of reduced dose craniospinal radiation (reduced from standard of care dosing at 36 Gy to 24 Gy) with concurrent carboplatin and vincristine administration for metastatic classical histology medulloblastomas and high-risk supratentorial PNETs and metastatic PNETs.
Gender:
ALL
Ages:
Between 3 years and 25 years
Trial Updated:
12/13/2021
Locations: Children's Hospital Colorado, Aurora, Colorado
Conditions: Metastatic Medulloblastoma, High Risk Supratentorial PNET, Metastatic PNET
Register for Updates
Ixabepilone and Carboplatin +/- Bevacizumab in Advanced Non-Small-Cell Lung Cancer
NCT00741988
Completed
This is a multicenter, non-randomized, Phase II study of patients with previously untreated NSCLC not amenable to radiotherapy or surgical treatment. The planned enrollment for this trial is 78 patients (including a 10% rate for inevaluable patients). There will be a total of 39 patients in each cohort (Cohorts A and B).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/13/2021
Locations: Florida Cancer Specialists, Fort Myers, Florida +12 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
A Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer
NCT03400306
Withdrawn
This study will evaluate the bioavailability between the veliparib tablet formulation to the capsule formulation; and will assess the effect of food on veliparib bioavailability in participants with ovarian cancer.
Gender:
FEMALE
Ages:
Between 18 years and 99 years
Trial Updated:
12/06/2021
Locations: Lifespan Cancer Institute /ID# 200130, Providence, Rhode Island +1 locations
Conditions: Cancer - Ovarian
Register for Updates
Randomized Trial of Neo-adjuvant Chemotherapy With or Without Metformin for HER2 Positive Operable Breast Cancer
NCT03238495
Unknown
The primary objective of this study is to determine the efficacy of metformin as a repurposed agent in human epidermal growth factor receptor 2 (HER2) positive breast cancer when added to standard neo-adjuvant chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
12/04/2021
Locations: The University of Kansas Cancer Center, West Clinic, Kansas City, Kansas +5 locations
Conditions: HER2-positive Breast Cancer
Register for Updates
Preoperative Chemotherapy and Bevacizumab in Patients With Stage IB (>4 cm), II, or Select Stage III NSCLC
NCT00960297
Terminated
The rationale for this multicenter, phase II trial is to examine the impact of carboplatin/paclitaxel with bevacizumab in the preoperative treatment of patients with stage IB (\> 4.0 cm), II, and select stage III NSCLC. If this novel regimen proves to be safe and active in this setting, this would provide rationale for further investigation in a larger, prospective, randomized setting.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
12/03/2021
Locations: Holy Cross Hospital, Fort Lauderdale, Florida +5 locations
Conditions: Non-Small Cell Lung Cancer
Register for Updates
Irinotecan, Carboplatin, and Sunitinib in First Line Extensive-Stage Small Cell Lung Cancer
NCT00695292
Completed
This proposed Phase II trial will investigate the combination of irinotecan and carboplatin followed by sunitinib in the first-line treatment of patients with extensive-stage SCLC.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/19/2021
Locations: Florida Cancer Specialists, Fort Myers, Florida +9 locations
Conditions: Small Cell Lung Cancer
Register for Updates
Chemotherapy, Radiotherapy and Bevacizumab in Patients With Unresectable Stage III Non-Small-Cell Lung Cancer
NCT00402883
Terminated
The purpose of this study is to see if this combination of chemotherapy plus radiation therapy and immunotherapy (with bevacizumab) expands treatment options for patients with non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
11/04/2021
Locations: Gainsville Hematology Oncology Associates, Gainesville, Florida +6 locations
Conditions: Lung Cancer
Register for Updates